Organon VTAMA Cream Gains Strong AAD Guideline Support
Jersey City, New Jersey, U.S. | April 15, 2026 Organon has announced that its VTAMA® (tapinarof) cream, 1% has...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Jersey City, New Jersey, U.S. | April 15, 2026 Organon has announced that its VTAMA® (tapinarof) cream, 1% has...
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
LOS ANGELES, USA | March 24, 2026 Turn Therapeutics, Inc., a clinical-stage dermatology-focused biotechnology company, has announced a strategic...
SAN FRANCISCO & BOSTON, USA | March 24, 2026 Apogee Therapeutics, Inc. has successfully announced the pricing of its...
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
FRIENDSWOOD, Texas, Feb. 19, 2026 — Castle Biosciences announced prospective clinical validation data published in the Journal of the...
PALO ALTO, Calif. & NEW YORK, Feb. 10, 2026 — Clinical-stage biotechnology company Evommune announced positive top-line results from...
SOUTH SAN FRANCISCO, CALIFORNIA | January 27, 2026 — TRexBio, Inc., a clinical-stage biotechnology company focused on precision immunoregulatory...
